Ignite Creation Date:
2025-12-24 @ 5:15 PM
Ignite Modification Date:
2025-12-25 @ 6:37 PM
Study NCT ID:
NCT05861050
Status:
RECRUITING
Last Update Posted:
2025-08-29
First Post:
2023-05-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Sponsor:
City of Hope Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-08-10
Start Date Type:
ACTUAL
Primary Completion Date:
2026-02-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-02-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-01
First Submit QC Date:
None
Study First Post Date:
2023-05-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-27
Last Update Post Date:
2025-08-29
Last Update Post Date Type:
ESTIMATED